$BCDA
BioCardia, Inc.

2024 Q3 Form 10-Q Financial Statement

#000143774924026310 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $3.000K $43.00K
YoY Change -100.0% -93.02% -95.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $825.0K $852.0K $1.181M
YoY Change -23.82% -27.86% 1.29%
% of Gross Profit
Research & Development $931.0K $800.0K $2.314M
YoY Change -50.27% -65.43% 0.43%
% of Gross Profit
Depreciation & Amortization $16.00K $17.00K $16.00K
YoY Change -23.81% 6.25% 0.0%
% of Gross Profit
Operating Expenses $1.756M $1.652M $3.495M
YoY Change -40.58% -52.73% 0.72%
Operating Profit -$1.756M -$1.649M -$3.452M
YoY Change -32.41% -52.23% 38.3%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $19.00K $3.000K $28.00K
YoY Change -20.83% -89.29% -2900.0%
Pretax Income -$1.737M -$1.646M -$3.424M
YoY Change -32.41% -51.93% 37.12%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.737M -$1.646M -$3.424M
YoY Change -32.52% -51.93% 37.12%
Net Earnings / Revenue -54866.67% -7962.79%
Basic Earnings Per Share -$0.61 -$0.88 -$0.17
Diluted Earnings Per Share -$0.61 -$0.88 -$0.17
COMMON SHARES
Basic Shares Outstanding 2.124M 27.30M 20.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.930M $1.421M $4.305M
YoY Change 167.93% -66.99% -50.02%
Cash & Equivalents $4.900M $1.400M $4.300M
Short-Term Investments
Other Short-Term Assets $116.0K $142.0K $230.0K
YoY Change -35.56% -38.26% -29.66%
Inventory
Prepaid Expenses
Receivables $10.00K $10.00K $115.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.056M $1.573M $4.650M
YoY Change 138.94% -66.17% -49.19%
LONG-TERM ASSETS
Property, Plant & Equipment $47.00K $61.00K $139.0K
YoY Change -58.77% -56.12% -31.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $171.0K $171.0K $171.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.211M $1.317M $1.739M
YoY Change -25.75% -24.27% -17.74%
TOTAL ASSETS
Total Short-Term Assets $5.056M $1.573M $4.650M
Total Long-Term Assets $1.211M $1.317M $1.739M
Total Assets $6.267M $2.890M $6.389M
YoY Change 67.25% -54.77% -43.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $569.0K $1.447M $686.0K
YoY Change 12.23% 110.93% -31.33%
Accrued Expenses $28.00K $4.000K $111.0K
YoY Change -22.22% -96.4% 282.76%
Deferred Revenue $333.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.840M $4.071M $3.616M
YoY Change -14.71% 12.58% 18.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $674.0K $780.0K $1.138M
YoY Change -37.59% -31.46% -23.0%
Total Long-Term Liabilities $674.0K $780.0K $1.138M
YoY Change -37.59% -31.46% -23.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.840M $4.071M $3.616M
Total Long-Term Liabilities $674.0K $780.0K $1.138M
Total Liabilities $3.514M $4.851M $4.754M
YoY Change -20.26% 2.04% 4.9%
SHAREHOLDERS EQUITY
Retained Earnings -$157.8M -$156.1M -$147.5M
YoY Change 5.13% 5.83% 9.67%
Common Stock $5.000K $2.000K $22.00K
YoY Change -77.27% -90.91% 22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.753M -$1.961M $1.635M
YoY Change
Total Liabilities & Shareholders Equity $6.267M $2.890M $6.389M
YoY Change 67.25% -54.77% -43.29%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.737M -$1.646M -$3.424M
YoY Change -32.52% -51.93% 37.12%
Depreciation, Depletion And Amortization $16.00K $17.00K $16.00K
YoY Change -23.81% 6.25% 0.0%
Cash From Operating Activities -$2.611M -$1.312M -$3.151M
YoY Change 8.34% -58.36% 19.13%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $3.000K $2.000K
YoY Change 50.0% -108.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K -$3.000K -$2.000K
YoY Change 50.0% -92.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.122M 1.787M 2.601M
YoY Change -10303.33% -31.3% 92.1%
NET CHANGE
Cash From Operating Activities -2.611M -1.312M -3.151M
Cash From Investing Activities -2.000K -3.000K -2.000K
Cash From Financing Activities 6.122M 1.787M 2.601M
Net Change In Cash 3.509M 472.0K -552.0K
YoY Change -242.06% -185.51% -58.05%
FREE CASH FLOW
Cash From Operating Activities -$2.611M -$1.312M -$3.151M
Capital Expenditures $2.000K $3.000K $2.000K
Free Cash Flow -$2.613M -$1.315M -$3.153M
YoY Change 8.42% -58.29% 20.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3424000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3913000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
278000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1900000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2123876
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1577769
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150570000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152175000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1603000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2987000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
58000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2314000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000925741
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.biocardia.com/20240630#CollaborationAgreementMember
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1421000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1103000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
34000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1573000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1461000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1085000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1261000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 usd
CY2024Q2 us-gaap Assets
Assets
2890000 usd
CY2023Q4 us-gaap Assets
Assets
2987000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1447000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
890000 usd
CY2024Q2 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2266000 usd
CY2023Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2385000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
358000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
333000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4071000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3608000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
780000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
982000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4851000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4590000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2123876
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1577769
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154125000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156088000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1961000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2890000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
107000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2041000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4698000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1181000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1941000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2371000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
3495000 usd
us-gaap Costs And Expenses
CostsAndExpenses
3982000 usd
us-gaap Costs And Expenses
CostsAndExpenses
7069000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3452000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3924000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6962000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6925000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.12
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1358968
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1776305
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1352094
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4892000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
317000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
177000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2471000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1635000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1603000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
43000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
832000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2275000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1961000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3913000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6925000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
176000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
159000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
388000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
595000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-34000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-87000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-86000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-153000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
561000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
69000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-119000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
353000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-177000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-153000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2842000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5711000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3315000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2950000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
152000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
285000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3163000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2665000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
318000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3058000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1103000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7363000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1421000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4305000 usd
us-gaap Stock Issued1
StockIssued1
66000 usd
us-gaap Stock Issued1
StockIssued1
106000 usd
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
0 usd
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
564000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156100000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1400000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(e)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash at times exceeds federally insured limits of $250,000 per customer. On June 30, 2024, approximately 96% of our cash and cash equivalents were held by one financial institution and total amounts on deposit were approximately $1.1 million in excess of FDIC insurance limits. We have not recognized any losses from credit risks on such accounts since inception.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2 bcda Cash Percentage Held In One Financial Institution
CashPercentageHeldInOneFinancialInstitution
0.96 pure
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1100000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
791000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
788000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
730000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
694000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
17000 usd
us-gaap Depreciation
Depreciation
36000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
21000 usd
us-gaap Depreciation
Depreciation
43000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
120000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
120000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
241000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
241000 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
121000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
242000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
118000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
236000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M2D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1074 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
242000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
499000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
514000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
44000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1299000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
161000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1138000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75000 usd
CY2024Q2 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
677000 usd
CY2023Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
661000 usd
CY2024Q2 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
1004000 usd
CY2023Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
1017000 usd
CY2024Q2 bcda Grant Liability Current
GrantLiabilityCurrent
470000 usd
CY2023Q4 bcda Grant Liability Current
GrantLiabilityCurrent
471000 usd
CY2024Q2 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
69000 usd
CY2023Q4 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000 usd
CY2024Q2 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2266000 usd
CY2023Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2385000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
141889
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
94.5
bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
67104
bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
6.6
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
208993
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
66.3
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
184000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
317000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
388000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
595000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
165784
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.67
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3177
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
6965
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
57.37
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
155642
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
106464
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
65.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
364635
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
335386
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(12)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-align: justify;">We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on our business, financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>

Files In Submission

Name View Source Status
0001437749-24-026310-index-headers.html Edgar Link pending
0001437749-24-026310-index.html Edgar Link pending
0001437749-24-026310.txt Edgar Link pending
0001437749-24-026310-xbrl.zip Edgar Link pending
bcda-20240630.xsd Edgar Link pending
bcda20240630_10q.htm Edgar Link pending
ex_709221.htm Edgar Link pending
ex_709222.htm Edgar Link pending
ex_709223.htm Edgar Link pending
ex_709224.htm Edgar Link pending
ex_710110.htm Edgar Link pending
ex_710111.htm Edgar Link pending
ex_710112.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
bcda-20240630_def.xml Edgar Link unprocessable
bcda-20240630_lab.xml Edgar Link unprocessable
bcda-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcda20240630_10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcda-20240630_cal.xml Edgar Link unprocessable